|
Volumn 62, Issue 13, 2013, Pages 1214-1215
|
Intracoronary versus intravenous abciximab bolus in patients with ST-segment elevation myocardial infarction: 1-year results of the randomized AIDA STEMI trial
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ABCIXIMAB;
ACETYLSALICYLIC ACID;
CLOPIDOGREL;
PRASUGREL;
BLOOD CLOT LYSIS;
BOLUS INJECTION;
CAUSE OF DEATH;
CONGESTIVE HEART FAILURE;
HEART FAILURE;
HEART REINFARCTION;
HUMAN;
LETTER;
MORTALITY;
PERCUTANEOUS CORONARY INTERVENTION;
PRIORITY JOURNAL;
RISK FACTOR;
ST SEGMENT ELEVATION MYOCARDIAL INFARCTION;
THROMBECTOMY;
ANTIBODIES, MONOCLONAL;
HUMANS;
IMMUNOGLOBULIN FAB FRAGMENTS;
INFUSIONS, INTRAVENOUS;
MYOCARDIAL INFARCTION;
PERCUTANEOUS CORONARY INTERVENTION;
PLATELET AGGREGATION INHIBITORS;
PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX;
|
EID: 84884394251
PISSN: 07351097
EISSN: 15583597
Source Type: Journal
DOI: 10.1016/j.jacc.2013.06.014 Document Type: Letter |
Times cited : (30)
|
References (3)
|